Table 3.
Dichotomized distribution of MPO and IL-17 according to defined cut-offs (22 cells/punch for MPO and 1 cell/punch for IL-17 [27] in primary carcinomas (n = 47)a
| MPO-/IL17- n = 21 (100 %) |
MPO+/IL17- n = 8 (100 %) |
MPO-/IL17+ n = 12 (100 %) |
MPO+/IL17+ n = 6 (100 %) |
p-value | |
|---|---|---|---|---|---|
| Age (median, range) | 62 (39–77) | 59.5 (50–65) | 57 (34–72) | 55 (45–73) | 0.742 |
| FIGO stage | |||||
| II | 0 | 0 | 1 (8.3) | 0 | 0.029 |
| IIIA | 1 (4.7) | 0 | 0 | 0 | |
| IIIB | 2 (9.5) | 0 | 0 | 3 (50.0) | |
| IIIC | 17 (81.1) | 5 (62.5) | 8 (66.7) | 2 (33.3) | |
| IV | 1 (4.7) | 3 (37.5) | 3 (25.0) | 1 (16.7) | |
| Residual disease | |||||
| None | 9 (42.9) | 2 (25.0) | 3 (25.0) | 2 (33.3) | 0.262 |
| <2 cm | 6 (28.6) | 1 (12.5) | 7 (58.3) | 3 (50.0) | |
| >2 cm | 5 (23.8) | 5 (62.5) | 2 (16.7) | 1 (16.7) | |
| Numbers of chemotherapy cycles | |||||
| <6 | 5 (23.8) | 0 | 1 (8.3) | 1 (16.7) | 0.412 |
| 6 or more | 15 (71.4) | 8 (100.0) | 11 (91.7) | 5 (83.3) | |
| CSb | 14 (66.7) | 2 (25.0) | 11 (91.7) | 6 (100.0) | 0.004 |
| CRb | 7 (33.3) | 6 (75.0) | 1 (8.3) | 0 | |
| RFSc (mean/SE) | 8.1 (1.7) | 3.9 (1.6) | 14.9 (3.3) | 16 (3.9) | 0.024 |
| OSc (mean/SE) | 36 (4.5) | 33.4 (9.6) | 52.4 (12.1) | 72 (15.0) | 0.113 |
Bold data statistically significant p < 0.05
apercentages may not add to 100 % due to missing values of defined variables, missing clinicopathological information was assumed to be missing at random. Variables are indicated as absolute numbers, %, median or range. Age, RFS and OS were evaluated using the Kruskal-Wallis test. FIGO stage, residual disease, numbers of chemotherapy cycles and chemoresistance were analyzed using the Fisher’s Exact test
b CS chemosensitive, CR chemoresistant
c RFS recurrence-free survival, OS overall survival